Claus Moller, departing CEO of Y-mAbs

Y-mAb­s' long­time CEO steps down abrupt­ly as FDA re­views sec­ond pe­di­atric can­cer drug

Over the past sev­en years, Claus Moller helped steer Y-mAbs Ther­a­peu­tics from a se­cre­tive Dan­ish biotech start­up laser-fo­cused on two pe­di­atric can­cer treat­ments to a Nas­daq-list­ed com­pa­ny boast­ing a three-pronged plat­form of im­munother­a­pies, ra­dio­ther­a­pies and com­pan­ion di­ag­nos­tics.

But as Y-mAbs gets deep­er in­to com­mer­cial­iza­tion, its long­time CEO is head­ing out.

Founder Thomas Gad — whose daugh­ter’s di­ag­no­sis of neu­rob­las­toma in­spired the com­pa­ny’s cre­ation by an ex-Gen­mab crew — will step in as in­ter­im CEO while Y-mAbs search­es for Moller’s per­ma­nent suc­ces­sor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.